The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 27, 2024
Filed:
Dec. 23, 2021
Hoffmann-la Roche Inc., Little Falls, NJ (US);
Shionogi & Co., Ltd., Osaka, JP;
Takeshi Noshi, Osaka, JP;
Takahiro Noda, Osaka, JP;
Ryu Yoshida, Osaka, JP;
Takao Shishido, Osaka, JP;
Kaoru Baba, Osaka, JP;
Aeron C. Hurt, Basel, CH;
Leo Yi Yang Lee, Melbourne, AU;
Steffen Wildum, Basel, CH;
Klaus Kuhlbusch, Basel, CH;
Barry Clinch, Basel, CH;
Jan Michal Nebesky, Basel, CH;
Annabelle Lemenuel, Basel, CH;
Wendy S. Barclay, London, GB;
Jean-Eric Charoin, Basel, CH;
Yoshinori Ando, Osaka, JP;
Shionogi & Co., Ltd., Osaka, JP;
Abstract
The present invention relates to a method for preventing transmission of influenza, wherein said method comprises administering an effective amount of a compound to a patient having an influenza virus infection, herein referred to as 'index patient', wherein the compound has one of the formulae (I) and (II), or its pharmaceutically acceptable salt. The compound to be used in the present invention reduces infectivity of the influenza virus of the index patient, and therefore, reduces the risk of the index patient to trigger an influenza epidemic or an influenza pandemic as compared to a control patient. Therefore, one aspect of the present invention relates to a method for preventing an influenza epidemic or an influenza pandemic, wherein the method comprises administering an effective amount of a compound to patients having an influenza virus infection (index patients), wherein the compound is administered to at least 10% of all influenza infected persons of a city's or country's population, and wherein the compound has one of the formulae (I) and (II), or is a pharmaceutically acceptable salt thereof.